Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase

Background Despite overexpression of the ErbB (EGFR/HER2/ErbB3/ErbB4) family in castration-resistant prostate cancer (CRPC), some inhibitors of this family, including the dual EGFR/HER2 inhibitor lapatinib, failed in Phase II clinical trials. Hence, we investigated mechanisms of lapatinib resistance...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2019-07, Vol.121 (3), p.237-248
Hauptverfasser:	Jathal, Maitreyee K., Steele, Thomas M., Siddiqui, Salma, Mooso, Benjamin A., D’Abronzo, Leandro S., Drake, Christiana M., Whang, Young E., Ghosh, Paramita M.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/589/466 692/4028/67/589/466 Animal models Animals Apoptosis Biomedical and Life Sciences Biomedicine Cancer Research Castration Cell Line, Tumor Cell viability Clinical trials Disease Models, Animal Drug Resistance Epidemiology Epidermal growth factor receptors ErbB protein ErbB Receptors - chemistry ErbB-2 protein ErbB-3 protein Humans Inhibitor drugs Inhibitors Lapatinib - therapeutic use Localization Male Membrane proteins Mice Mice, Inbred BALB C Molecular Medicine Oncology Patients Prostate cancer Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - metabolism Protein Multimerization Proteins Quinazolinones - therapeutic use Receptor, ErbB-2 - biosynthesis Receptor, ErbB-2 - blood Receptor, ErbB-2 - chemistry Targeted cancer therapy Tumors Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!